(Total Views: 161)
Posted On: 07/15/2019 9:20:50 AM
Post# of 36519
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting
9:15 AM ET, 07/15/2019 - GlobeNewswire
Olaregen Silver SponsorshipDr. Lois Chandler, PhD Presents Excellagen Research as Keynote Speaker at Wound Care SymposiumRapid Acceleration of Healing with Wound Conforming, Native Structural Matrix - New Alternative to Sheet-Based Skin Substitutes
MIRAMAR, Fla., July 15, 2019 (GLOBE NEWSWIRE) -- /PRNewswire/--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company was a Silver Sponsor of the American Podiatric Medicine Association (APMA) annual scientific meeting held in Salt Lake City, Utah from July 11 – 14, 2019. Founded in 1912, the APMA is the leading resource for foot and ankle health information, and the annual scientific meeting is the premier forum for the dissemination of education, research results, and new product innovations in podiatric medicine.
Olaregen sponsored one of the APMA’s leading educational programs: Saturday July 13th, Rapid Acceleration of Healing with Wound Conforming, Native Structural Matrix - New Alternative to Sheet-Based Skin Substitutes. Dr. Lois Chandler, PhD, the inventor of Excellagen wound conforming matrix presented the keynote address. The program was attended by over 100 APMA physicians and was highly interactive with great interest in the clinical efficacy and ease of use of Excellagen.
Olaregen also had a large exhibit at the APMA meeting, highlighting the use of Excellagen® for wound management and providing education and demonstrations for the attendees, which included thousands of foot and ankle physicians, assistants, and related foot and ankle professionals.
“We are proud of our strong relationship with the APMA, and we are happy to sponsor these important scientific sessions to disseminate cutting edge research results on regenerative medicine to the podiatry community,” said Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex, “The APMA has awarded their coveted Seal of Approval to Excellagen, and we look forward to building our relationship and continuing our support of the Association’s goals to improve the practice of podiatric medicine.”
9:15 AM ET, 07/15/2019 - GlobeNewswire
Olaregen Silver SponsorshipDr. Lois Chandler, PhD Presents Excellagen Research as Keynote Speaker at Wound Care SymposiumRapid Acceleration of Healing with Wound Conforming, Native Structural Matrix - New Alternative to Sheet-Based Skin Substitutes
MIRAMAR, Fla., July 15, 2019 (GLOBE NEWSWIRE) -- /PRNewswire/--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company was a Silver Sponsor of the American Podiatric Medicine Association (APMA) annual scientific meeting held in Salt Lake City, Utah from July 11 – 14, 2019. Founded in 1912, the APMA is the leading resource for foot and ankle health information, and the annual scientific meeting is the premier forum for the dissemination of education, research results, and new product innovations in podiatric medicine.
Olaregen sponsored one of the APMA’s leading educational programs: Saturday July 13th, Rapid Acceleration of Healing with Wound Conforming, Native Structural Matrix - New Alternative to Sheet-Based Skin Substitutes. Dr. Lois Chandler, PhD, the inventor of Excellagen wound conforming matrix presented the keynote address. The program was attended by over 100 APMA physicians and was highly interactive with great interest in the clinical efficacy and ease of use of Excellagen.
Olaregen also had a large exhibit at the APMA meeting, highlighting the use of Excellagen® for wound management and providing education and demonstrations for the attendees, which included thousands of foot and ankle physicians, assistants, and related foot and ankle professionals.
“We are proud of our strong relationship with the APMA, and we are happy to sponsor these important scientific sessions to disseminate cutting edge research results on regenerative medicine to the podiatry community,” said Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex, “The APMA has awarded their coveted Seal of Approval to Excellagen, and we look forward to building our relationship and continuing our support of the Association’s goals to improve the practice of podiatric medicine.”
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)